AOP Orphan Pharmaceuticals AG

Quick facts

Marketed products

• Brevibloc · Cardiovascular
• Standard of Care - Double Oral · Cardiovascular
  This is a standard-of-care dual oral antithrombotic regimen combining two antiplatelet or anticoagulant agents to prevent thrombotic events.

Phase 3 pipeline

• Anagrelide retard · Hematology/Oncology
  Anagrelide is a phosphodiesterase 3 inhibitor that reduces platelet production by inhibiting megakaryocyte maturation and proliferation.
• Peg-P-IFN-alpha-2b (AOP2014) · Virology / Immunology
  Peg-P-IFN-alpha-2b is a pegylated interferon alpha-2b that activates innate immune responses to suppress viral replication and enhance antiviral immunity.
• Pegylated-Proline-interferon alpha-2b · Virology/Hepatology
  Pegylated-Proline-interferon alpha-2b is a modified interferon alpha-2b with extended half-life that activates innate immune responses through interferon-alpha receptor signaling.
• preservative-free parenteral treprostinil · Cardiovascular
  Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.
• Thromboreductin · Cardiovascular

Phase 2 pipeline

• AOP200704
• Esmolol hydrochloride, infusion
• Moli1901

Phase 1 pipeline

• LDLA202
• LDLL600
• ONO LDL50

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AOP Orphan Pharmaceuticals AG portfolio CI brief
• AOP Orphan Pharmaceuticals AG pipeline updates RSS